Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(9%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_2
4
36%
Ph phase_4
3
27%
Ph not_applicable
3
27%
Ph phase_1
1
9%

Phase Distribution

1

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 4Post-market surveillance
3(27.3%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(4)
Other(6)

Detailed Status

unknown6
Completed4
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (9.1%)
Phase 24 (36.4%)
Phase 43 (27.3%)
N/A3 (27.3%)

Trials by Status

recruiting19%
completed436%
unknown655%

Recent Activity

1 active trials
Showing 5 of 11
completedphase_4

Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

NCT00200356
recruitingnot_applicable

Edaravone in the Treatment of Optic Neuritis

NCT05540262
unknownphase_2

Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury

NCT03968042
unknownphase_2

The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS

NCT04391361
unknownphase_2

Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03272802
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT00200356Phase 4

Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

Completed
NCT05540262Not Applicable

Edaravone in the Treatment of Optic Neuritis

Recruiting
NCT03968042Phase 2

Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury

Unknown
NCT04391361Phase 2

The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS

Unknown
NCT03272802Phase 2

Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)

Unknown
NCT02644915Not Applicable

Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients

Unknown
NCT00265239Phase 4

Pilot Study of Edaravone to Treat Acute Myocardial Infarction

Completed
NCT01894334Not Applicable

Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection

Unknown
NCT01865201Phase 2

Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis

Completed
NCT01518231Phase 1

Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke

Unknown
NCT00153946Phase 4

Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11